Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066578 | 1.00 | F10 (0.43) | F10SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL4876097 | 0.85 | F10 (0.38) | F10SMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL4710501 | 0.84 | RAB9A (0.42) | SMN1; SMN2MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL4873941 | 0.83 | GRM5 (0.40) | F10SMN1; SMN2KMT2ALMNAKDM4E | |
| SCHEMBL14066579 | 0.83 | GRM5 (0.40) | F10SMN1; SMN2KMT2ALMNAKDM4E | |
| SCHEMBL4877155 | 0.79 | F10 (0.40) | F10SMN1; SMN2F2LMNANPC1 | |
| SCHEMBL4875148 | 0.79 | RAB9A (0.41) | F10SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL14066580 | 0.79 | MAPT (0.53) | SMN1; SMN2MEN1KMT2AKDM4EPOLB | |
| SCHEMBL4878300 | 0.78 | F10 (0.38) | F10SMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4884604 | 0.77 | POLB (0.49) | SMN1; SMN2CYP1A2CYP2D6CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | F10 26/4885SMN1; SMN2 2534/4885MEN1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.